TAMAURA BAUGHMAN: Open Payments
NPI 1437520921 · KINGWOOD, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$555 in 25 payments from 11 companies in 2025. Trend: 2023 $589 · 2024 $445 · 2025 $555
Food & beverage: $555
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $112 |
| Otsuka America Pharmaceutical, Inc. | 5 | $100 |
| Novo Nordisk Inc | 4 | $81 |
| Corcept Therapeutics | 3 | $76 |
| Sumitomo Pharma America, Inc. | 2 | $49 |
| Exact Sciences Corporation | 2 | $34 |
| Astellas Pharma US Inc | 1 | $30 |
| Lundbeck LLC | 1 | $23 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $18 |
| AstraZeneca Pharmaceuticals LP | 1 | $16 |
Products named: REXULTI, CAPLYTA, Korlym, Wegovy, GEMTESA, Cologuard Collection Kit, Veozah, XIFAXAN.
Industry payments across TX — which companies pay providers there.
